Yangli Pharmaceutical completed a 100-million-yuan Series B financing round, exclusively invested by Qiming Venture Partners.
Recently, Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Yangli Pharmaceutical"), an innovative drug R & D company, announced the completion of a 100 - million - level Series B financing round. This round of financing was exclusively invested by Qiming Venture Partners. The company's existing shareholders also include Taifu Capital, Hangzhou State - owned Assets, and Runzhang Venture Capital. The funds from this round of financing will be used for the clinical advancement of the company's multiple products.
Founded in 2021, Yangli Pharmaceutical is based in Hangzhou. Rooted in China and benchmarking against international standards, it focuses on researching and developing Class 1 innovative drugs with global intellectual property rights, which are first - in - class or best - in - class. It focuses on anti - tumor and chronic disease therapies, and several of its products have entered Phase I and Phase II clinical trials.
Yangli Pharmaceutical has gathered world - class drug innovation experts and management talents. The core founding team of the company graduated from Tsinghua University, University of California, Los Angeles, State University of New York, West China School of Medicine, Sichuan University (formerly West China Medical University), The University of Hong Kong, etc.
Dr. Sha Wei, the founder and president of Yangli Pharmaceutical, has rich industrial experience. Before founding Yangli Pharmaceutical, Dr. Sha Wei served as the general manager of Taifeng Research Institute of Taifeng Pharmaceutical Group, the founding shareholder of Yangli Pharmaceutical. Her experience comprehensively covers the entire process from drug R & D to product launch, laying a solid foundation for the company's innovative drug R & D and industrialization.
Dr. Ding Zhaozhong, the co - founder and chairman of Yangli Pharmaceutical, has more than 30 years of experience in drug R & D and management, bringing valuable R & D experience to Yangli Pharmaceutical.
Dr. Fang Dong, the chief scientific officer of Yangli Pharmaceutical, brings more than 20 years of experience in drug discovery and development. Dr. Fang Dong has participated in the R & D of several anti - tumor new drugs on the market, such as Lisaftoclax, Olverembatinib, Iruplinalkib, and Glasdegib, and promoted dozens of new drug clinical trial applications in China and the United States. He has published more than 40 peer - reviewed scientific papers and holds more than 20 patents.
The strong talent team provides the core driving force for the company's innovative drug R & D. Currently, significant progress has been made in the R & D of multiple innovative drugs of Yangli Pharmaceutical, covering the fields of hypertension and various solid tumors. The products in clinical trials include the highly selective aldosterone synthase inhibitor VB19055 and small - molecule targeted drugs - TFX05, TFX06, VB15. The pre - clinical small - molecule and small - nucleic - acid pipelines cover diseases such as tumors, hypertension, hyperlipidemia, and diabetes.
Yangli Pharmaceutical has won a series of honors for its outstanding performance in the field of innovative drugs, including being recognized as a national high - tech enterprise, a national technology - based small and medium - sized enterprise, an innovative small and medium - sized enterprise in Zhejiang Province, a talent - leading demonstration enterprise in 2024, and the ninth batch of "Dayun Talents" innovation and entrepreneurship projects.
Dr. Ding Zhaozhong, the co - founder and chairman of Yangli Pharmaceutical, said: " We are grateful for the consistent trust and support of various investment institutions in Yangli Pharmaceutical. Since its establishment, the company has been conducting source - based R & D of differentiated products around unmet clinical needs, following the R & D concept of 'In China, For Global'. We have built anti - tumor and chronic disease pipelines using our advantageous small - molecule and small - nucleic - acid technology platforms. The successful completion of this round of financing fully demonstrates the investors' high recognition of the clinical competitiveness and market potential of our pipelines. This financing paves the way for our anti - tumor product line to enter registration - based clinical trials and for our chronic disease products to obtain clinical validation. It marks that Yangli Pharmaceutical has entered a stage of rapid development and is one step closer to the commercialization of innovative drugs. We will aim to pursue value enhancement for investors and bring well - being to patients' health as our goal and mission."
Dr. Chen Kan, a partner of Qiming Venture Partners and the co - head of the medical innovation industry, said: "Yangli Pharmaceutical creates differentiated innovation from the source with its forward - looking target project establishment and efficient compound optimization platform, and has developed a series of candidate molecules with high activity, high specificity, and excellent safety." We believe that driven by the company's strong clinical development capabilities, these molecules will quickly move from the pipeline to the market, and their huge clinical value and market potential will be released, ultimately meeting the urgent clinical needs of global patients.
This article is from the WeChat official account "Qiming Venture Partners", and is published by 36Kr with authorization.